JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Evaluation of second-line treatment options in metastatic esophageal squamous cell carcinoma
Abstract
Aims: Esophageal cancer is the seventh most common cause of death worldwide and the survival rate of patients with metastatic esophageal cancer is very low. Although current guidelines recommend immunotherapy as a second-line treatment for esophageal squamous cell carcinoma (SCC), a significant proportion of patients have difficulty accessing this treatment. Therefore, conventional chemotherapy is used as second-line treatment. In this study, we aimed to compare the efficacy and tolerability of irinotecan- and taxane-containing chemotherapy regimens as second-line treatments for patients with disease progression after first-line cytotoxic chemotherapy.
Methods: This study included 43 patients with metastatic esophageal SCC at the time of diagnosis or relapse during follow-up. The patients were divided into two groups: irinotecan-based chemotherapy regimens (n=21) and taxane-based chemotherapy regimens (n=22). Demographic characteristics, treatment regimens, treatment responses, grade 3-4 toxicities, overall survival (OS), and progression-free survival (PFS) were documented and analyzed using appropriate statistical methods.
Results: Of the 43 patients who received second-line treatment, 25 (58.1%) were male and 18 (41.9%) were female. The mean age was 55.86±11.6 years. At the time of diagnosis, 72.1% of the patients had metastatic disease. The median OS was 5 months (95% CI, 2.5 to 7.4) for the irinotecan-based regimen and 10 months (95% CI, 2.6 to 17.3) for the taxane-based regimen (p=0.122). The median PFS was 4 months (95% CI, 2.9 to 5.0) in the irinotecan-based regimen group and 7 months (95% CI, 4.8 to 9.1) in the taxane-based regimen group (p= 0.80). There were no significant differences in OS and PFS between the two groups. Grade 3-4 neutropenia (p=0.046) and grade 3-4 neuropathy (p=0.034) were higher in the group receiving taxane-based regimens, while grade 3-4 mucositis (p=0.027) was higher in the group receiving irinotecan-based regimens. There were no statistically significant differences in other side effects (p>0.05).
Conclusion: We found no statistically significant difference in the median PFS and median OS between the two chemotherapy groups used as second-line treatment for metastatic esophageal SCC. Grade 3-4 neutropenia and grade 3-4 neuropathy were higher in the group receiving taxane-based regimens, while grade 3-4 mucositis was higher in the group receiving irinotecan-based regimens. Although our study has limitations, such as its retrospective and single-center nature, it is one of the few studies performed in this patient group in recent years and is important because it reflects our clinical practice.

Keywords : Esophageal cancer, squamous cell carcinoma, second-line treatment

Download Article


1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10. 3322/caac.21834
2. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95(18):1404-1413. doi:10.1093/jnci/djg047
3. Baquet CR, Commiskey P, Mack K, Meltzer S, Mishra SI. Esophageal cancer epidemiology in blacks and whites: racial and gender disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2005;97(11):1471-1478.
4. Chen Z, Ren Y, Du XL, et al. Incidence and survival differences in esophageal cancer among ethnic groups in the United States. Oncotarget. 2017;8(29):47037-47051. doi:10.18632/oncotarget.16694
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34. doi:10.3322/caac.21551
6. Obermannová R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992-1004. doi:10.1016/j.annonc.2022.07.003
7. Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(4):393-422. doi:10.6004/jnccn.2023.0019
8. Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20(3):343-372. doi:10.1007/s10388-023-00993-2
9. Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265-1272. doi:10.1007/s00280-010-1422-x
10. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955-959. doi:10.1093/annonc/mdh231
11. Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res. 2007;27(4C):2845-2848.
12. Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 Study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138-4148. doi:10.1200/JCO.20.01888
13. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(11):1506-1517. doi:10.1016/S1470-2045(19)30626-6
14. Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832-842. doi:10.1016/S1470-2045(20)30110-8
15. Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40(26):3065-3076. doi:10.1200/JCO.21.01926
16. Janmaat VT, Steyerberg EW, van der Gaast A, et al. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 2017; 11(11):CD004063. doi:10.1002/14651858.CD004063.pub4
17. Shirakawa T, Kato K, Nagashima K, et al. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol. 2014; 74(6):1207-1215. doi:10.1007/s00280-014-2597-3
18. Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol. 2011;29(35): 4709-4714. doi:10.1200/JCO.2011.36.7599
19. Abraham P, Gricar J, Zhang Y, Shankaran V. Real-World treatment patterns and outcomes in patients receiving second-line therapy for advanced/metastatic esophageal squamous cell carcinoma. Adv Ther. 2020;37(7):3392-3403. doi:10.1007/s12325-020-01394-y
20. Mizota A, Shitara K, Kondo C, et al. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology. 2011;81(3-4):237-242. doi:10.1159/000334057
21. Guner G, Sezgin Y. Comparison of the efficacy of dual chemotherapy regimens in second-line treatment of metastatic esophageal squamous cell carcinoma. Eurasian J Med Investigation. 2024;8(1):48-53. doi:10. 14744/ejmi.2023.20180
Article available in :
Volume 3, Issue 2, 2025
Page : 27-31
https://doi.org/10.51271/JCHOR-0058
Article Information
Received : 30 Ara 2024
Accepted : 03 Şub 2025
Published : 08 May 2025
Corresponding Author :

Yonca Yılmaz Ürün: Department of Gastroenterology and Hepatology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Turkiye

[email protected]
Citation : Yılmaz Ürün Y, Ürün M. Evaluation of second-line treatment options in metastatic esophageal squamous cell carcinoma. J Curr Hematol Oncol Res. 2025;3(2):27-31.

Read: 182
Download : 297
Cited: 0
_Footer